Artificial intelligence (AI) has been the word of 2023, but aside from the promises, what are the realities of its practical implementation in the life sciences setting?
Despite the economic downturn, UK life sciences companies raised a healthy £382 million ($486 million) in new financing in the second quarter of the year, with venture cap
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh